Response prediction biomarkers and drug combinations of PARP inhibitors in prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Response prediction biomarkers and drug combinations of PARP inhibitors in prostate cancer

Published:2021-02-15 Issue:12 Volume:42 Page:1970-1980
ISSN:1671-4083
Container-title:Acta Pharmacologica Sinica
language:en
Short-container-title:Acta Pharmacol Sin

Author:

Chen Yi-xin,Tan Li-ming,Gong Jian-ping,Huang Ma-sha,Yin Ji-ye,Zhang Wei,Zhou Hong-hao,Liu Zhao-qian

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.nature.com/articles/s41401-020-00604-1.pdf

Reference123 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.

2. Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer. 2014;120:818–23.

3. Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209–23.

4. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–79.

5. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review of computational methods for predicting cancer drug response at the single-cell level through integration with bulk RNAseq data;Current Opinion in Structural Biology;2024-02

2. Upregulation of PARG in prostate cancer cells suppresses their malignant behavior and downregulates tumor-promoting genes;Biomedicine & Pharmacotherapy;2022-09

3. Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics;Cancer Letters;2022-04

4. Nanotherapeutic macrophage-based immunotherapy for the peritoneal carcinomatosis of lung cancer;Nanoscale;2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3